In an attempt to mitigate the dose-limiting thrombocytopenia associated with the mixed BCL-2/BCL-XL inhibitor, navitoclax, this agent was combined with both the selective BCL-2 inhibitor, venetoclax, and low-intensity vincristine-based chemotherapy in a phase 1 trial of R/R B-ALL and T-ALL across all ages [144]. This evidence concerns the gene BCL2 and Thrombocytopenia.